4//SEC Filing
Hoberman Kenneth 4
Accession 0001104659-20-071835
CIK 0001264587other
Filed
Jun 9, 8:00 PM ET
Accepted
Jun 10, 11:18 AM ET
Size
11.4 KB
Accession
0001104659-20-071835
Insider Transaction Report
Form 4
Hoberman Kenneth
Chief Operating Officer
Transactions
- Disposition from Tender
Common Stock
2020-06-10−1,374,352→ 0 total - Disposition to Issuer
Employee Stock Option (right to buy)
2020-06-10−44,058→ 0 totalExercise: $4.12Exp: 2026-02-24→ Common Stock (44,058 underlying) - Disposition to Issuer
Employee Stock Option (right to buy)
2020-06-10−25,000→ 0 totalExercise: $5.77Exp: 2026-01-07→ Common Stock (25,000 underlying) - Award
Common Stock
2020-06-10+600,000→ 1,374,352 total
Footnotes (4)
- [F1]Represents previously-granted performance-based awards that became vested under the agreement and plan of merger among Issuer, Berlin-Chemie AG, and Mercury Merger Sub, Inc., dated as of May 3, 2020 (the "Merger Agreement").
- [F2]Disposed of in connection with a tender offer made pursuant to the Merger Agreement, in exchange for $11.50 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share (collectively, the "Offer Price"). Each CVR represents the right to receive a payment of $1.00 in cash upon the achievement of a certain milestone relating to the first sale of ELZONRIS in any one of certain countries following a marketing authorization approval by the European Commission. The CVR milestone must be achieved on or prior to December 31, 2021.
- [F3]All options were vested and exercisable as of the effective time of the merger.
- [F4]Disposed of under the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option.
Documents
Issuer
STEMLINE THERAPEUTICS INC
CIK 0001264587
Entity typeother
Related Parties
1- filerCIK 0001573722
Filing Metadata
- Form type
- 4
- Filed
- Jun 9, 8:00 PM ET
- Accepted
- Jun 10, 11:18 AM ET
- Size
- 11.4 KB